Clinical Implications of Our Advancing Knowledge of Colorectal Cancer Genetics: Inherited Syndromes, Prognosis, Prevention, Screening and Therapeutics

Surgical Clinics of North America

Volumn 86, Issue 4, 2006, Pages 787-817

  Gryfe, Robert ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APC PROTEIN; BEVACIZUMAB; CALCIUM CARBONATE; CELECOXIB; CETUXIMAB; DACARBAZINE; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; METHOTREXATE; MICROSATELLITE DNA; MISMATCH REPAIR PROTEIN PMS2; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P53; REPETITIVE DNA; ROFECOXIB; SELENIUM; SULINDAC; TAMOXIFEN; VINBLASTINE;

ADENOMATOUS POLYP; ALLELE; AMINO ACID SUBSTITUTION; ANEUPLOIDY; AUTOSOMAL DOMINANT DISORDER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER GROWTH; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHROMOSOMAL INSTABILITY; CHROMOSOME 17P; CHROMOSOME 18Q; CHROMOSOME 5Q; CLINICAL TRIAL; COLON CANCER; COLON RESECTION; COLONOSCOPY; COLORECTAL CANCER; COMPARATIVE GENOMIC HYBRIDIZATION; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; COWDEN SYNDROME; DESMOID TUMOR; DNA CONTENT; DNA FINGERPRINTING; DNA REPLICATION; DNA SEQUENCE; DRUG COST; DRUG FATALITY; DUODENUM CANCER; DUODENUM POLYP; ENDOMETRIUM CANCER; ESOPHAGOGASTRODUODENOSCOPY; FAMILIAL CANCER; GEL ELECTROPHORESIS; GENE MUTATION; GENE OVEREXPRESSION; GENETIC COUNSELING; GENETIC MARKER; GLIOBLASTOMA; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEART FAILURE; HEART INFARCTION; HETEROZYGOSITY LOSS; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; ILEOSTOMY; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; INFORMED CONSENT; INTESTINE POLYP; KERATOACANTHOMA; LINKAGE ANALYSIS; LUNG NON SMALL CELL CANCER; MEDULLOBLASTOMA; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MISSENSE MUTATION; MUIR TORRE SYNDROME; NUCLEOTIDE SEQUENCE; OCCULT BLOOD TEST; ONCOGENE; OVARY CANCER; PANCREAS CANCER; PATHOLOGY; PEUTZ JEGHERS SYNDROME; PIGMENT EPITHELIUM; PREVALENCE; PRIORITY JOURNAL; PROCTOCOLECTOMY; PROPHYLAXIS; PROTEIN EXPRESSION; RECTUM CANCER; REVIEW; SALPINGOOOPHORECTOMY; SEBACEOUS GLAND; SEBACEOUS GLAND TUMOR; SIGMOIDOSCOPY; SIGNAL TRANSDUCTION; STOMACH POLYP; STROKE; SURGICAL TECHNIQUE; THROMBOSIS; THYROID CANCER; TUMOR SUPPRESSOR GENE; TURCOT SYNDROME;

ADENOMATOUS POLYPOSIS COLI; ANTICARCINOGENIC AGENTS; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; GENETIC SCREENING; NEOPLASTIC SYNDROMES, HEREDITARY; PROGNOSIS;

EID: 33746899721     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2006.05.007     Document Type: Review

References (147)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
2. Vogelstein B., Fearon E.R., Hamilton S.R., et al. Genetic alterations during colorectal-tumor development. N Engl J Med 319 (1988) 525-532
3. Fearon E.R., and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61 (1990) 759-767
4. Vogelstein B., and Kinzler K.W. Cancer genes and the pathways they control. Nat Med 10 (2004) 789-799
5. Boland C.R., and Goel A. Somatic evolution of cancer cells. Semin Cancer Biol 15 (2005) 436-450
6. Burt R., and Neklason D.W. Genetic testing for inherited colon cancer. Gastroenterology 128 (2005) 1696-1716
7. de la Chapelle A. Genetic predisposition to colorectal cancer. Nat Rev Cancer 4 (2004) 769-780
8. Knudsen A.L., Bisgaard M.L., and Bulow S. Attenuated familial adenomatous polyposis (AFAP). A review of the literature. Fam Cancer 2 (2003) 43-55
9. King J.E., Dozois R.R., Lindor N.M., et al. Care of patients and their families with familial adenomatous polyposis. Mayo Clin Proc 75 (2000) 57-67
10. Belchetz L.A., Berk T., Bapat B.V., et al. Changing causes of mortality in patients with familial adenomatous polyposis. Dis Colon Rectum 39 (1996) 384-387
11. Church J., and Simmang C. Practice parameters for the treatment of patients with dominantly inherited colorectal cancer (familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer). Dis Colon Rectum 46 (2003) 1001-1012
12. American Gastroenterological Association medical position statement: hereditary colorectal cancer and genetic testing. Gastroenterology 121 (2001) 195-197
13. Kinzler K.W., Nilbert M.C., Su L.K., et al. Identification of FAP locus genes from chromosome 5q21. Science 253 (1991) 661-665
14. Nishisho I., Nakamura Y., Miyoshi Y., et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 253 (1991) 665-669
15. Powell S.M., Zilz N., Beazer-Barclay Y., et al. APC mutations occur early during colorectal tumorigenesis. Nature 359 (1992) 235-237
16. Kinzler K.W., and Vogelstein B. Lessons from hereditary colorectal cancer. Cell 87 (1996) 159-170
17. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 21 (2003) 2397-2406
18. Laurent-Puig P., Beroud C., and Soussi T. APC gene: database of germline and somatic mutations in human tumors and cell lines. Nucleic Acids Res 26 (1998) 269-270
19. Powell S.M., Petersen G.M., Krush A.J., et al. Molecular diagnosis of familial adenomatous polyposis. N Engl J Med 329 (1993) 1982-1987
20. Giardiello F.M., Brensinger J.D., Petersen G.M., et al. The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. N Engl J Med 336 (1997) 823-827
21. Laken S.J., Petersen G.M., Gruber S.B., et al. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet 17 (1997) 79-83
22. Gryfe R., Di Nicola N., Gallinger S., et al. Somatic instability of the APC I1307K allele in colorectal neoplasia. Cancer Res 58 (1998) 4040-4043
23. Gryfe R., Di Nicola N., Lal G., et al. Inherited colorectal polyposis and cancer risk of the APC I1307K polymorphism. Am J Hum Genet 64 (1999) 378-384
24. Genetic testing for colon cancer: joint statement of the American College of Medical Genetics and American Society of Human Genetics. Joint Test and Technology Transfer Committee Working Group. Genet Med 2 (2000) 362-366
25. Winawer S., Fletcher R., Rex D., et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 124 (2003) 544-560
26. Smith R.A., Cokkinides V., and Eyre H.J. American Cancer Society guidelines for the early detection of cancer, 2003. CA Cancer J Clin 53 (2003) 27-43
27. Al-Tassan N., Chmiel N.H., Maynard J., et al. Inherited variants of MYH associated with somatic G:C→T:A mutations in colorectal tumors. Nat Genet 30 (2002) 227-232
28. Sieber O.M., Lipton L., Crabtree M., et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med 348 (2003) 791-799
29. Croitoru M.E., Cleary S.P., Di Nicola N., et al. Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk. J Natl Cancer Inst 96 (2004) 1631-1634
30. Nielsen M., Franken P.F., Reinards T.H., et al. Multiplicity in polyp count and extracolonic manifestations in 40 Dutch patients with MYH associated polyposis coli (MAP). J Med Genet 42 (2005) e54
31. Baglioni S., Melean G., Gensini F., et al. A kindred with MYH-associated polyposis and pilomatricomas. Am J Med Genet A 134 (2005) 212-214
32. Umar A., Boland C.R., Terdiman J.P., et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96 (2004) 261-268
33. Hampel H., Stephens J.A., Pukkala E., et al. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 129 (2005) 415-421
34. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al. A National Cancer Institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997;89:1758-10.
35. Dunlop M.G., Farrington S.M., Carothers A.D., et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 6 (1997) 105-110
36. Hamilton S.R., Liu B., Parsons R.E., et al. The molecular basis of Turcot's syndrome. N Engl J Med 332 (1995) 839-847
37. Ponti G., and Ponz de Leon M. Muir-Torre syndrome. Lancet Oncol 6 (2005) 980-987
38. Gryfe R., Kim H., Hsieh E.T., et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342 (2000) 69-77
39. Kim H., Jen J., Vogelstein B., et al. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 145 (1994) 148-156
40. Aaltonen L.A., Peltomaki P., Leach F.S., et al. Clues to the pathogenesis of familial colorectal cancer. Science 260 (1993) 812-816
41. Peltomaki P., and Vasen H. Mutations associated with HNPCC predisposition-update of ICG-HNPCC/INSiGHT mutation database. Dis Markers 20 (2004) 269-276
42. Ionov Y., Peinado M.A., Malkhosyan S., et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363 (1993) 558-561
43. Thibodeau S.N., Bren G., and Schaid D. Microsatellite instability in cancer of the proximal colon. Science 260 (1993) 816-819
44. Boland C.R., Thibodeau S.N., Hamilton S.R., et al. A National Cancer Institute wworkshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58 (1998) 5248-5257
45. Ricciardone M.D., Ozcelik T., Cevher B., et al. Human MLH1 deficiency predisposes to hematological malignancy and neurofibromatosis type 1. Cancer Res 59 (1999) 290-293
46. Gill S., Lindor N.M., Burgart L.J., et al. Isolated loss of PMS2 expression in colorectal cancers: frequency, patient age, and familial aggregation. Clin Cancer Res 11 (2005) 6466-6471
47. Hampel H., Frankel W.L., Martin E., et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352 (2005) 1851-1860
48. Nystrom-Lahti M., Kristo P., Nicolaides N.C., et al. Founding mutations and Alu-mediated recombination in hereditary colon cancer. Nat Med 1 (1995) 1203-1206
49. Gille J.J., Hogervorst F.B., Pals G., et al. Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected by a novel mutation detection approach. Br J Cancer 87 (2002) 892-897
50. Raevaara T.E., Korhonen M.K., Lohi H., et al. Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1. Gastroenterology 129 (2005) 537-549
51. de Vos tot Nederveen Cappel W.H., Nagengast F.M., Griffioen G., et al. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis Colon Rectum 45 (2002) 1588-1594
52. Burke W., Petersen G., Lynch P., et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. JAMA 277 (1997) 915-919
53. Schmeler K.M., Lynch H.T., Chen L.M., et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354 (2006) 261-269
54. Lindor N.M., Rabe K., Petersen G.M., et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 293 (2005) 1979-1985
55. Hemminki A., Markie D., Tomlinson I., et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 391 (1998) 184-187
56. Jenne D.E., Reimann H., Nezu J., et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 18 (1998) 38-43
57. Chow E., and Macrae F. A review of juvenile polyposis syndrome. J Gastroenterol Hepatol 20 (2005) 1634-1640
58. Howe J.R., Roth S., Ringold J.C., et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science 280 (1998) 1086-1088
59. Howe J.R., Bair J.L., Sayed M.G., et al. Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet 28 (2001) 184-187
60. Marsh D.J., Dahia P.L., Zheng Z., et al. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet 16 (1997) 333-334
61. Liaw D., Marsh D.J., Li J., et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16 (1997) 64-67
62. Kinzler K.W., and Vogelstein B. Landscaping the cancer terrain. Science 280 (1998) 1036-1037
63. Bast Jr. R.C., Ravdin P., Hayes D.F., et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19 (2001) 1865-1878
64. Compton C.C., Fielding L.P., Burgart L.J., et al. Prognostic factors in colorectal cancer. College of American Pathologists consensus statement 1999. Arch Pathol Lab Med 124 (2000) 979-994
65. Allen W.L., and Johnston P.G. Role of genomic markers in colorectal cancer treatment. J Clin Oncol 23 (2005) 4545-4552
66. Davies R.J., Miller R., and Coleman N. Colorectal cancer screening: prospects for molecular stool analysis. Nat Rev Cancer 5 (2005) 199-209
67. Hawk E.T., and Levin B. Colorectal cancer prevention. J Clin Oncol 23 (2005) 378-391
68. Pantaleo M.A., Palassini E., Labianca R., et al. Targeted therapy in colorectal cancer: do we know enough?. Dig Liver Dis 38 (2006) 71-77
69. Kane M.F., Loda M., Gaida G.M., et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 57 (1997) 808-811
70. Toyota M., Ahuja N., Ohe-Toyota M., et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 96 (1999) 8681-8686
71. Samowitz W.S., Albertsen H., Herrick J., et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 129 (2005) 837-845
72. Samowitz W.S., Curtin K., Ma K.N., et al. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev 10 (2001) 917-923
73. Benatti P., Gafa R., Barana D., et al. Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res 11 (2005) 8332-8340
74. Popat S., Hubner R., and Houlston R.S. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23 (2005) 609-618
75. Ribic C.M., Sargent D.J., Moore M.J., et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349 (2003) 247-257
76. Barratt P.L., Seymour M.T., Stenning S.P., et al. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet 360 (2002) 1381-1391
77. Carethers J.M., Smith E.J., Behling C.A., et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 126 (2004) 394-401
78. Jover R., Zapater P., Castells A., et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy on colorectal cancer. Gut 55 (2006) 848-855
79. Elsaleh H., and Iacopetta B. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma. Clin Colorectal Cancer 1 (2001) 104-109
80. Figueredo A., Fine S., Maroun J., et al. Adjuvant therapy for stage III colon cancer after complete resection. Provincial Gastrointestinal Disease Site Group. Cancer Prev Control 1 (1997) 304-319
81. Figueredo A., Germond C., Maroun J., et al. Adjuvant therapy for stage II colon cancer after complete resection. Provincial Gastrointestinal Disease Site Group. Cancer Prev Control 1 (1997) 379-392
82. Fallik D., Borrini F., Boige V., et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res 63 (2003) 5738-5744
83. Vendrell E., Morales C., Risques R.A., et al. Genomic determinants of prognosis in colorectal cancer. Cancer Lett 221 (2005) 1-9
84. Rajagopalan H., Nowak M.A., Vogelstein B., et al. The significance of unstable chromosomes in colorectal cancer. Nat Rev Cancer 3 (2003) 695-701
85. Lanza G., Gafa R., Santini A., et al. Prognostic significance of DNA ploidy in patients with stage II and stage III colon carcinoma: a prospective flow cytometric study. Cancer 82 (1998) 49-59
86. Bardi G., Fenger C., Johansson B., et al. Tumor karyotype predicts clinical outcome in colorectal cancer patients. J Clin Oncol 22 (2004) 2623-2634
87. Risques R.A., Moreno V., Ribas M., et al. Genetic pathways and genome-wide determinants of clinical outcome in colorectal cancer. Cancer Res 63 (2003) 7206-7214
88. Kern S.E., Fearon E.R., Tersmette K.W., et al. Clinical and pathological associations with allelic loss in colorectal carcinoma. [corrected]. JAMA 261 (1989) 3099-3103
89. Vogelstein B., Fearon E.R., Kern S.E., et al. Allelotype of colorectal carcinomas. Science 244 (1989) 207-211
90. Riggins G.J., Thiagalingam S., Rozenblum E., et al. Mad-related genes in the human. Nat Genet 13 (1996) 347-349
91. Popat S., and Houlston R.S. A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer 41 (2005) 2060-2070
92. Munro A.J., Lain S., and Lane D.P. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 92 (2005) 434-444
93. Baker S.J., Fearon E.R., Nigro J.M., et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244 (1989) 217-221
94. Baas I.O., Mulder J.W., Offerhaus G.J., et al. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172 (1994) 5-12
95. Allegra C.J., Paik S., Colangelo L.H., et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 21 (2003) 241-250
96. Fearon E.R., Cho K.R., Nigro J.M., et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 247 (1990) 49-56
97. Jen J., Kim H., Piantadosi S., et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 331 (1994) 213-221
98. Goel A., Arnold C.N., Niedzwiecki D., et al. Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res 63 (2003) 1608-1614
99. Konishi M., Kikuchi-Yanoshita R., Tanaka K., et al. Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, familial polyposis, and sporadic colon cancer. Gastroenterology 111 (1996) 307-317
100. Formentini A., Henne-Bruns D., and Kornmann M. Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: a review. Langenbecks Arch Surg 389 (2004) 405-413
101. Popat S., Matakidou A., and Houlston R.S. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 22 (2004) 529-536
102. Edler D., Glimelius B., Hallstrom M., et al. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 20 (2002) 1721-1728
103. Anwar S., Frayling I.M., Scott N.A., et al. Systematic review of genetic influences on the prognosis of colorectal cancer. Br J Surg 91 (2004) 1275-1291
104. Adlard J.W., Richman S.D., Seymour M.T., et al. Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol 3 (2002) 75-82
105. McDermott U., Longley D.B., and Johnston P.G. Molecular and biochemical markers in colorectal cancer. Ann Oncol 13 Suppl 4 (2002) 235-245
106. Wang Y., Jatkoe T., Zhang Y., et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 22 (2004) 1564-1571
107. Ghadimi B.M., Grade M., Difilippantonio M.J., et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 23 (2005) 1826-1838
108. Allal A.S., Kahne T., Reverdin A.K., et al. Radioresistance-related proteins in rectal cancer. Proteomics 4 (2004) 2261-2269
109. Diehl F., Li M., Dressman D., et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 102 (2005) 16368-16373
110. Osborn N.K., and Ahlquist D.A. Stool screening for colorectal cancer: molecular approaches. Gastroenterology 128 (2005) 192-206
111. Imperiale T.F., Ransohoff D.F., Itzkowitz S.H., et al. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 351 (2004) 2704-2714
112. Woolf S.H. A smarter strategy? Reflections on fecal DNA screening for colorectal cancer. N Engl J Med 351 (2004) 2755-2758
113. Raju R., and Cruz-Correa M. Chemoprevention of colorectal cancer. Dis Colon Rectum 49 (2006) 113-124 [discussion: 24-5]
114. Brown J.R., and DuBois R.N. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 23 (2005) 2840-2855
115. Dannenberg A.J., Altorki N.K., Boyle J.O., et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2 (2001) 544-551
116. Stark L.A., Din F.V., Zwacka R.M., et al. Aspirin-induced activation of the NF-kappaB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB J 15 (2001) 1273-1275
117. Eberhart C.E., Coffey R.J., Radhika A., et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107 (1994) 1183-1188
118. Subbaramaiah K., Altorki N., Chung W.J., et al. Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 274 (1999) 10911-10915
119. Oshima M., Dinchuk J.E., Kargman S.L., et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87 (1996) 803-809
120. Jacoby R.F., Seibert K., Cole C.E., et al. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 60 (2000) 5040-5044
121. Sandler R.S., Halabi S., Baron J.A., et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348 (2003) 883-890
122. Baron J.A., Cole B.F., Sandler R.S., et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348 (2003) 891-899
123. Solomon S.D., McMurray J.J., Pfeffer M.A., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080
124. Bresalier R.S., Sandler R.S., Quan H., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1092-1102
125. Giardiello F.M., Hamilton S.R., Krush A.J., et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328 (1993) 1313-1316
126. Steinbach G., Lynch P.M., Phillips R.K., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342 (2000) 1946-1952
127. Niv Y., and Fraser G.M. Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy. Gastroenterology 107 (1994) 854-857
128. Thorson A.G., Lynch H.T., and Smyrk T.C. Rectal cancer in FAP patient after sulindac. Lancet 343 (1994) 180
129. Giardiello F.M., Yang V.W., Hylind L.M., et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 346 (2002) 1054-1059
130. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results fFrom the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
131. Lamprecht S.A., and Lipkin M. Chemoprevention of colon cancer by calcium, vitamin D and folate: molecular mechanisms. Nat Rev Cancer 3 (2003) 601-614
132. Bautista D., Obrador A., Moreno V., et al. Ki-ras mutation modifies the protective effect of dietary monounsaturated fat and calcium on sporadic colorectal cancer. Cancer Epidemiol Biomarkers Prev 6 (1997) 57-61
133. Borgelt L., and Umland E. Benefits and challenges of hormone replacement therapy. J Am Pharm Assoc (Wash) 40 (2000) S30-S31
134. Duffield-Lillico A.J., Shureiqi I., and Lippman S.M. Can selenium prevent colorectal cancer? A signpost from epidemiology. J Natl Cancer Inst 96 (2004) 1645-1647
135. Schrag D. The price tag on progress-chemotherapy for colorectal cancer. N Engl J Med 351 (2004) 317-319
136. Chung K.Y., and Saltz L.B. Antibody-based therapies for colorectal cancer. Oncologist 10 (2005) 701-709
137. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
138. Hurwitz H.I., Fehrenbacher L., Hainsworth J.D., et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23 (2005) 3502-3508
139. Kabbinavar F.F., Hambleton J., Mass R.D., et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23 (2005) 3706-3712
140. Spano J.P., Fagard R., Soria J.C., et al. Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. Ann Oncol 16 (2005) 189-194
141. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
142. Barber T.D., Vogelstein B., Kinzler K.W., et al. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 351 (2004) 2883
143. Tsuchihashi Z., Khambata-Ford S., Hanna N., et al. Responsiveness to cetuximab without mutations in EGFR. N Engl J Med 353 (2005) 208-209
144. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
145. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
146. Suter C.M., Martin D.I., and Ward R.L. Germline epimutation of MLH1 in individuals with multiple cancers. Nat Genet 36 (2004) 497-501
147. Cunningham J.M., Kim C.Y., Christensen E.R., et al. The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Hum Genet 69 (2001) 780-790